Oshima Kiyohiro, Takeyoshi Izumi, Tsutsumi Hirofumi, Mohara Jun, Ohki Shigeru, Koike Norimasa, Nameki Taro, Matsumoto Koshi, Morishita Yasuo
Department of Thoracic and Visceral Organ Surgery, Gunma University Graduate School of Medicine, Maebashi, Gunma 371-8511, Japan.
J Surg Res. 2006 Oct;135(2):380-4. doi: 10.1016/j.jss.2006.03.044. Epub 2006 May 19.
Cyclooxygenase (COX) is an intracellular enzyme that converts arachidonic acid to prostaglandin endoperoxide (PGG(2)). There are two isoforms of COX, namely constitutive COX-1 and inducible COX-2. It has been reported that COX-2 plays an important role in ischemia-reperfusion injury and that COX-2 mRNA and protein expression were up-regulated during cardiac allograft rejection. FK3311 is a suppressor of COX-2 activation. The purpose of this study was to evaluate the effectiveness of inhibiting COX-2 with FK3311 for the minimization of ischemia-reperfusion injury and for the improvement of donor heart function following transplantation in a canine model.
Adult mongrel dogs were used. After the measurement of hemodynamic parameters [cardiac output (CO), left ventricular pressure (LVP), and the maximum rates of increase and decrease in LVP (+/-LVdp/dt)], coronary vascular beds were washed out with a hypothermic (4 degrees C) University of Wisconsin (UW) solution following cardiac arrest in response to cold (4 degrees C) glucose-insulin-potassium solution. The heart was then excised and preserved in hypothermic (4 degrees C) UW solution for 12 h. FK3311 (3 mg/kg) was administered intravenously to five dogs prior to reperfusion, while vehicle was administered intravenously to a control group (n = 5). After 3 h of orthotopic transplantation using cardiopulmonary bypass, the hemodynamic parameters were compared with preoperative values of the donor animals under the condition of 10 mm Hg right atrial pressure and 5 mug/kg/min dopamine support.
The recovery rates of CO and +/-LVdP/dt were significantly (P < 0.05) higher in the FK-treated dogs than in the controls (CO: 93 +/- 6 versus 66% +/- 4%; +LVdp/dt: 125 +/- 8 versus 77 +/- 10%; and -LVdp/dt: 81 +/- 7 versus 52 +/- 6%; for FK-treated versus control dogs, respectively). The recovery rate of LVP was higher in the FK-treated dogs than in the controls (90 +/- 5 versus 72 +/- 5%), but this difference was not statistically significant. Immunohistochemical staining revealed that COX-2 expression was reduced significantly in the myocardium of FK-treated dogs compared with controls.
Hemodynamic parameters following transplantation were improved significantly in dogs treated with FK3311. Therefore, the inhibition of COX-2 improves transplanted cardiac function following long-term preservation.
环氧化酶(COX)是一种将花生四烯酸转化为前列腺素内过氧化物(PGG₂)的细胞内酶。COX有两种同工型,即组成型COX-1和诱导型COX-2。据报道,COX-2在缺血再灌注损伤中起重要作用,并且在心脏移植排斥反应期间COX-2 mRNA和蛋白表达上调。FK3311是COX-2激活的抑制剂。本研究的目的是评估在犬模型中用FK3311抑制COX-2以最小化缺血再灌注损伤并改善移植后供心功能的有效性。
使用成年杂种犬。在测量血流动力学参数[心输出量(CO)、左心室压力(LVP)以及LVP的最大上升和下降速率(±LVdp/dt)]后,在心脏因冷(4℃)葡萄糖-胰岛素-钾溶液停搏后,用低温(4℃)威斯康星大学(UW)溶液冲洗冠状动脉床。然后切除心脏并在低温(4℃)UW溶液中保存12小时。在再灌注前,对五只犬静脉注射FK3311(3mg/kg),而对对照组(n = 5)静脉注射赋形剂。在使用体外循环进行原位移植3小时后,在右心房压力为10mmHg和多巴胺支持量为5μg/kg/min的条件下,将血流动力学参数与供体动物的术前值进行比较。
FK治疗组犬的CO和±LVdP/dt恢复率显著高于对照组(P < 0.)(CO:93±6对66%±4%;+LVdp/dt:125±8对77±10%;-LVdp/dt:81±7对52±6%,分别为FK治疗组犬和对照组犬)。FK治疗组犬的LVP恢复率高于对照组(90±5对72±5%),但这种差异无统计学意义。免疫组织化学染色显示,与对照组相比,FK治疗组犬心肌中COX-2表达显著降低。
用FK3311治疗的犬移植后的血流动力学参数显著改善。因此,抑制COX-2可改善长期保存后的移植心脏功能。